X

Drug Profile

Research programme: p38/MEK-targeting molecules - Signal Research Division

Alternative Names: p38/MEK-targeting molecules research programme - Signal Research Division

Latest Information Update: 26 Apr 2007

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Signal Research Division
Class
Mechanism of Action Mitogen-activated protein kinase kinase inhibitors; P38 mitogen-activated protein kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cancer; Rheumatoid arthritis

Most Recent Events

07 Nov 2003 This programme is still in active development
07 Sep 2000 Signal Pharmaceuticals has been acquired by Celgene
26 Jan 2000 Available for licensing (http://www.signalpharm.com)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com